Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).

Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP.

Clin Exp Rheumatol. 2019 Apr 16. [Epub ahead of print]

PMID:
31025930
2.

[Pulmonary involvement in rheumatoid arthritis].

Krause A, Rubbert-Roth A.

Z Rheumatol. 2019 Apr;78(3):228-235. doi: 10.1007/s00393-019-0611-1. Review. German.

PMID:
30887119
3.

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K.

Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Review. German.

PMID:
29968101
4.

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL.

Lancet. 2018 Jun 23;391(10139):2513-2524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18.

PMID:
29908670
5.

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E.

Rheumatol Ther. 2018 Jun;5(1):21-42. doi: 10.1007/s40744-018-0102-x. Epub 2018 Mar 3. Review.

6.

[Lymphoma in rheumatic diseases].

Rubbert-Roth A, Bittenbring JT, Assmann G.

Z Rheumatol. 2017 Oct;76(Suppl 2):46-56. doi: 10.1007/s00393-017-0383-4. Review. German.

PMID:
29330755
7.

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.

Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, Elbez Y, Rauch C.

Arthritis Res Ther. 2018 Jan 2;20(1):1. doi: 10.1186/s13075-017-1488-5.

8.

TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?

Rubbert-Roth A, Atzeni F, Masala IF, Caporali R, Montecucco C, Sarzi-Puttini P.

Autoimmun Rev. 2018 Jan;17(1):24-28. doi: 10.1016/j.autrev.2017.11.005. Epub 2017 Nov 3. Review.

PMID:
29108829
9.

[51-year-old man with with acute coronary syndrome and bipulmonary infiltrates].

Michels G, Radtke A, Rubbert-Roth A, Pfister R, Quaas A.

Dtsch Med Wochenschr. 2017 Oct;142(20):1545. doi: 10.1055/s-0043-111114. Epub 2017 Oct 10. German. No abstract available.

PMID:
29017214
10.

A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement.

Rubbert-Roth A, Jacobs JWG, Bijlsma JWJ, Welsing PMJ.

Ann Rheum Dis. 2018 Jul;77(7):1085-1086. doi: 10.1136/annrheumdis-2017-211485. Epub 2017 Jun 23. No abstract available.

PMID:
28646081
11.

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S.

Ann Rheum Dis. 2017 Jul;76(7):1279-1284. doi: 10.1136/annrheumdis-2016-210561. Epub 2017 Apr 7.

12.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

13.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

14.

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.

Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, Dimonaco S, Rubbert-Roth A, van Vollenhoven R, Genovese MC.

Rheumatology (Oxford). 2017 Apr 1;56(4):541-549. doi: 10.1093/rheumatology/kew370. Review.

15.

Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Choy E, Aletaha D, Behrens F, Finckh A, Gomez-Reino J, Gottenberg JE, Schuch F, Rubbert-Roth A.

Rheumatology (Oxford). 2017 May 1;56(5):689-697. doi: 10.1093/rheumatology/kew271. Review.

PMID:
27550301
16.

Antigen-presenting human B cells are expanded in inflammatory conditions.

Shimabukuro-Vornhagen A, García-Márquez M, Fischer RN, Iltgen-Breburda J, Fiedler A, Wennhold K, Rappl G, Abken H, Lehmann C, Herling M, Wolf D, Fätkenheuer G, Rubbert-Roth A, Hallek M, Theurich S, von Bergwelt-Baildon M.

J Leukoc Biol. 2017 Feb;101(2):577-587. doi: 10.1189/jlb.5A0416-182R. Epub 2016 Aug 17.

PMID:
27534894
17.

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

Rubbert-Roth A, Sebba A, Brockwell L, Kelman A, Porter-Brown B, Pulley J, Napalkov P, van Vollenhoven RF.

RMD Open. 2016 May 10;2(1):e000213. doi: 10.1136/rmdopen-2015-000213. eCollection 2016.

18.

Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.

Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, Alison K, Toft M, Kouloumas M, Ferreira RJ, Oliver S, Rubbert-Roth A, van Assen S, Dixon WG, Finckh A, Zink A, Kremer J, Kvien TK, Nurmohamed M, van der Heijde D, Dougados M.

Ann Rheum Dis. 2016 Jun;75(6):965-73. doi: 10.1136/annrheumdis-2016-209233. Epub 2016 Mar 16. Review.

19.

[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].

Rubbert-Roth A, Zander T, Kneitz C, Baerwald C, Wirtz H, Witt C.

Z Rheumatol. 2016 Feb;75(1):47-53. doi: 10.1007/s00393-016-0043-0. Review. German.

PMID:
26838521
20.

[Do we still need clinical studies in rheumatology?].

Henkemeier U, Alten R, Bannert B, Baraliakos X, Behrens F, Heldmann F, Kiltz U, Köhm M, König R, Leipe J, Müller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, Schulze-Koops H, Specker C, Tausche AK, Wassenberg S, Witt M, Witte T, Zernicke J, Burkhardt H.

Z Rheumatol. 2016 Feb;75(1):4-10. doi: 10.1007/s00393-015-1687-x. German.

PMID:
26680367
21.

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N.

Ann Rheum Dis. 2016 Jun;75(6):1081-91. doi: 10.1136/annrheumdis-2015-207628. Epub 2015 Oct 28.

22.

[Differential diagnosis of polyarthritis].

Rubbert-Roth A.

Dtsch Med Wochenschr. 2015 Jul;140(15):1125-30. doi: 10.1055/s-0041-103627. Epub 2015 Jul 31. Review. German. No abstract available.

PMID:
26230064
23.

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).

Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Bao M, Rowell L, Davies C, Mysler EF.

Ann Rheum Dis. 2016 Jan;75(1):68-74. doi: 10.1136/annrheumdis-2015-207281. Epub 2015 Jun 8.

24.

[Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].

Rubbert-Roth A.

Z Rheumatol. 2015 Jun;74(5):406-13. doi: 10.1007/s00393-014-1533-6. German.

PMID:
26031285
25.

Spectrum of Uveitis in A German Tertiary Center: Review of 474 Consecutive Patients.

Grajewski RS, Caramoy A, Frank KF, Rubbert-Roth A, Fätkenheuer G, Kirchhof B, Cursiefen C, Heindl LM.

Ocul Immunol Inflamm. 2015 Aug;23(4):346-352. doi: 10.3109/09273948.2014.1002567. Epub 2015 Mar 11.

PMID:
25760917
26.

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.

Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE.

Ann Rheum Dis. 2015 Jul;74(7):1474-8. doi: 10.1136/annrheumdis-2014-206016. Epub 2015 Feb 20.

27.

Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics.

Verheyen J, Maizus K, Feist E, Tolman Z, Knops E, Saech J, Spengler L, Waterboer T, Burmester GR, Pawlita M, Pfister H, Rubbert-Roth A.

Med Microbiol Immunol. 2015 Oct;204(5):613-8. doi: 10.1007/s00430-015-0390-5. Epub 2015 Feb 13.

PMID:
25678083
28.

[Recommendations on the use of rituximab for ANCA-associated vasculitis].

Gause AM, Rubbert-Roth A; Kommission für Pharmakotherapie.

Z Rheumatol. 2014 Apr;73(3):287-9. doi: 10.1007/s00393-013-1318-3. German.

PMID:
27039911
29.

Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients.

Wendler J, Burmester GR, Sörensen H, Krause A, Richter C, Tony HP, Rubbert-Roth A, Bartz-Bazzanella P, Wassenberg S, Haug-Rost I, Dörner T.

Arthritis Res Ther. 2014 Mar 26;16(2):R80. doi: 10.1186/ar4521.

30.

[Recommendations for use of rituximab in patients with rheumatoid arthritis].

Rubbert-Roth A, Burmester GR, Dörner T, Gause A; Kommission Pharmakotherapie der DGRh.

Z Rheumatol. 2014 Mar;73(2):165-74. doi: 10.1007/s00393-013-1238-2. German.

PMID:
24659153
31.

[Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

Tarner IH, Albrecht K, Fleck M, Gromnica-Ihle E, Keyßer G, Köhler L, Kötter I, Krüger K, Kuipers J, Nüßlein H, Rubbert-Roth A, Wollenhaupt J, Schneider M, Manger B, Müller-Ladner U; internationalen 3e-Initiative.

Z Rheumatol. 2014 May;73(4):363-73. doi: 10.1007/s00393-013-1249-z. German.

PMID:
24590079
32.

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H.

Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17.

33.

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.

Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, Barile-Fabris L, Moots RJ, Ostor A, Andrianakos A, Gemmen E, Mpofu C, Chung C, Gylvin LH, Finckh A.

Ann Rheum Dis. 2015 Jun;74(6):979-84. doi: 10.1136/annrheumdis-2013-203993. Epub 2014 Jan 17.

34.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

35.

German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.

Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; German Society of Rheumatology.

Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14. Review.

PMID:
23942828
36.

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).

Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, Rowell L, Bao M, Mysler EF.

Ann Rheum Dis. 2014 Jan;73(1):69-74. doi: 10.1136/annrheumdis-2013-203523. Epub 2013 Jul 31.

37.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348. No abstract available.

PMID:
23532441
38.

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, Van Vollenhoven R.

J Rheumatol. 2013 Jun;40(6):768-80. doi: 10.3899/jrheum.120687. Epub 2013 Mar 1.

PMID:
23457383
39.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

40.

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).

Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP.

J Rheumatol. 2012 Nov;39(11):2153-6. doi: 10.3899/jrheum.120482. Epub 2012 Sep 15.

PMID:
22984269
41.

[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Krüger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; European League of Associations for Rheumatology (EULAR).

Z Rheumatol. 2012 Sep;71(7):592-603. doi: 10.1007/s00393-012-1038-0. German.

PMID:
22930110
42.

[Nervous system side effects of disease modifying treatments of rheumatoid arthritis].

Rubbert-Roth A, Petereit HF.

Z Rheumatol. 2012 Sep;71(7):572-82. doi: 10.1007/s00393-012-0959-y. German.

PMID:
22930108
43.

[New kinase inhibitors].

Rubbert-Roth A.

Z Rheumatol. 2012 Aug;71(6):479-84. doi: 10.1007/s00393-011-0880-9. German.

PMID:
22777068
44.

Assessing the safety of biologic agents in patients with rheumatoid arthritis.

Rubbert-Roth A.

Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v38-47. doi: 10.1093/rheumatology/kes114. Review.

PMID:
22718926
45.

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.

Pavelka K, Kavanaugh AF, Rubbert-Roth A, Ferraccioli G.

Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v12-21. doi: 10.1093/rheumatology/kes111. Review.

PMID:
22718922
46.

[Orphan diseases in rheumatology. Exemplified by polyarteritis nodosa].

Rubbert-Roth A.

Z Rheumatol. 2012 Feb;71(2):119-21. doi: 10.1007/s00393-011-0902-7. Review. German.

PMID:
22370802
47.

To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50.

Buch MH, Rubbert-Roth A, Ferraccioli G.

Autoimmun Rev. 2012 Jun;11(8):558-62. doi: 10.1016/j.autrev.2011.10.012. Epub 2011 Oct 22. Review.

PMID:
22037117
48.

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T.

Ann Rheum Dis. 2012 Mar;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170. Epub 2011 Oct 19.

49.

[Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis].

Kalden JR, Burkhardt H, Buss B, Donhauser-Gruber U, Erstling U, Gromnica-Ihle E, Karberg K, Karger T, Kneitz CH, Krause A, Krüger K, Lorenz HM, Müller-Ladner U, Rubbert-Roth A, Steffens-Korbanka P, Tony HP, Wendler J, Wollenhaupt J, Burmester G.

Z Rheumatol. 2011 Oct;70(8):641-50. doi: 10.1007/s00393-011-0763-0. Review. German.

PMID:
21979315
50.

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.

Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Müller-Ladner U, Gaylis NB, Williams S, Reynard M, Tyrrell H.

Rheumatology (Oxford). 2011 Dec;50(12):2223-32. doi: 10.1093/rheumatology/ker253. Epub 2011 Sep 16.

Supplemental Content

Loading ...
Support Center